Home
overview
70 million US citizens are suffering from gastrointestinal diseases, which greatly impact on direct and indirect healthcare costs. However, there is a distinct lack of targeted drug discovery for the majority of gastrointestinal disorders. Drug discovery for gastrointestinal tract diseases is predominantly reliant on programmes for other indications.

SMi’s Emerging and Existing Gastrointestinal Drugs will keep all those involved in gastric cancer, irritable bowel syndrome, inflammatory bowel disease, and gastroenterological infections up to date with the current needs, developments and technologies. As a senior industry executive, you will be aware of the importance and potential of this field. We would therefore like to invite you to register for Emerging and Existing Gastrointestinal Drugs. As you will see from the brochure, key speakers include representatives from leading pharmaceutical and biotechnology companies.

The conference offers you the opportunity to network with key industry experts. Benefit from the practical insight and hard advice provided by an outstanding panel of speakers. Attend to discover the potential and realities of gastrointestinal disease therapies, and to match your company’s resources to the needs of the patient.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Jorg Täubel,

Dr Jorg Täubel,, Medical Director, Charterhouse Clinical Research Unit

9:10 ADDRESSING THE PROBLEM OF GASTROINTESTINAL DISORDERS

Dr Andrew Sutton

Dr Andrew Sutton, Medical Director, Guilford Clinical Pharmacology Unit

  • Gastrointestinal disorders as targets for new drug developments
  • Advances in the understanding of target gastrointestinal disorders
  • Specific problems of trial methodology in gastrointestinal disorders
  • Limitations of currently available therapies
  • Integrating new developments
  • Meeting the needs of patients
  • 9:40 HEAT SHOCK PROTEIN VACCINES FOR GASTRIC AND COLORECTAL CANCERS

    Dr Michael Heike

    Dr Michael Heike, Attending Physician, University Clinic of Mainz

  • Current concepts for vaccination against cancer
  • Heat shock proteins as immunotherapeutic vaccines against cancer: how do they work?
  • Ongoing clinical trials in gastrointestinal cancer
  • Future strategies for immunotherapy with heat shock protein vaccines in gastrointestinal cancer
  • Possible impact on future treatment of gastrointestinal cancer
  • 10:20 ANTI-GASTRIN IMMUNOTHERAPY OF GASTROINTESTINAL ADENOCARCINOMAS: AN INNOVATIVE APPROACH

    Dr Sue Watson Apht

    Dr Sue Watson Apht, Director, Cancer Studies Unit, Queens Medical Centre, University of Nottingham, Aphton

  • Using its innovative vaccine-like technology for neutralising hormones within the gastrointestinal system
  • The anti-gastrin immunogen therapy: how does it work?
  • Involvement of gastrin receptors in the development of colon cancer
  • Inhibiting the endocrine and autocrine humoral pathways
  • Joining into strategic alliances
  • Anticipating the future of treating gastric and colon cancer
  • 11:00 Morning Coffee

    11:20 TREATING GASTRIC CANCER WITH THERAGYN

    Dr Luiz Porto

    Dr Luiz Porto, DirectorClinical Research and Development, Antisoma

  • Developing Theragyn
  • Mechanism of action of Theragyn
  • Entering into phase II clinical study of Theragyn with gastric cancer patients
  • Commercial protection in the major markets
  • Building up their position within the gastric cancer field
  • 12:00 CONTROLLING HELICOBACTER PYLORI INFECTION

    Dr Rino Rappuoli

    Dr Rino Rappuoli, Vice President, Vaccine Research, Chiron

  • Helicobacter pylori, the major cause of stomach ulcer and gastric cancer
  • The clinical need for a vaccine capable of controlling Helicobacter pylori infection
  • A promising approach to eradicate Helicobacter pylori
  • Identifying key bacterial proteins that are important for Helicobacter pylori infection
  • Developing vaccine candidates that have shown protection against Helicobacter pylori in preclinical models
  • Pharmacoeconomical aspects of a vaccine against Helicobacter pylori
  • 12:40 Lunch

    14:00 CONTRIBUTING TO THE TREATMENT OF HELICOBACTER PYLORI INFECTION

    Dr David A Zopf

    Dr David A Zopf, Vice President, Drug Development, Neose Technologies

  • The involvement of carbohydrate ligands in infection
  • Mechanism of action of NE-0080
  • Demonstrating safety and efficacy of NE-0080
  • The potential role of NE-0080 in anti-Helicobacter pylori regimens
  • MTR - an enabling technology creating a new class of pharmaceuticals
  • Broad potential of complex carbohydrates in treatment of GI disorders
  • 14:40 DEVELOPING VACCINES BASED ON THE GHOST TECHNOLOGY

    Dr Florian Schoedel

    Dr Florian Schoedel, Vice President, Research and Development, Evax Technologies

  • Developing a new class of mucosal bacterial vaccines based on its proprietary bacterial ghost technology
  • Producing empty bacterial envelopes, known as bacterial ghosts
  • Retaining critical antigens on the bacterial cell surface in their native form
  • Stimulating protective immune responses
  • Pharmacoeconomic implications
  • 15:20 Afternoon Tea

    15:40 DEVELOPING CARBOHYDRATE-BASED THERAPEUTICS FOR VEROTOXIGENIC E COLI INFECTIONS

    Dr David Cox

    Dr David Cox, President and Chief Executive Officer, SYNSORB Biotech

  • Focusing on products for gastrointestinal problems
  • Developing SynsorbPk®
  • Mechanism of action of SynsorbPk®
  • Taking SynsorbPk® into clinical trials
  • Safety and efficacy of SynsorbPk®
  • Benefits of SynsorbPk® for the patient
  • 16:20 CONTRIBUTING TO THE TREATMENT OF SHORT BOWEL SYNDROME

    Dr Dan Drucker

    Dr Dan Drucker, Director, Division of Endocrinology, Professor of Medicine, University of Toronto

  • Involvement of GLP-2 receptor in intestinal growth and nutrition absorption
  • Cloning the receptor for Glucagon-like peptide 2 (GLP-2)
  • Localised expression of the GLP-2 receptor within the gastrointestinal tract
  • Developing ALX-0600 - strategies
  • Increasing the absorptive area of the small intestine
  • Minimising side-effects of ALX-0600
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:10 Chairman's Opening Remarks

    Dr Jean Pierre Isal

    Dr Jean Pierre Isal, Senior Vice President, Drug Development Europe, Quintiles

    9:10 PLANNING A SUCCESSFUL RESEARCH COLLABORATION

    Matthew M Warren

    Matthew M Warren, Partner, Bristows

  • Contractual collaborations, joint venture companies and partnerships
  • Management and control of the collaboration
  • Ownership and exploitation of intellectual property rights
  • Payment structures
  • Exit routes from the collaboration
  • 9:40 DESIGNING REGISTRATION STRATEGIES

    John Kolthammer

    John Kolthammer, Vice President, European Regulatory Affairs, ,Phoenix International

  • Factors involved in developing a regulatory strategy for filing a new application
  • Working closely with the regulatory authorities throughout the whole drug development process
  • Strategic planning for meetings with the authorities
  • Meeting the needs of the regulatory authorities
  • Regulatory considerations in different countries
  • 10:20 APPROACHING THE DEVELOPMENT PATHWAY

    Dr Michael Young

    Dr Michael Young, Chief Scientific Officer, Medeva

  • Understanding the market opportunity for the demonstrated therapeutic potential
  • Exploring potential advantages over currently available treatments
  • Moving a product into commercial development
  • Assessing safety and efficacy of a new product
  • Identifying critical values needed for a successful product launch
  • 11:00 Morning Coffee

    11:20 CREATING A GASTROINTESTINAL PORTFOLIO IN AN EMERGING BIOPHARMACEUTICAL COMPANY

    Dr Richard Palmer

    Dr Richard Palmer, Chief Executive Officer, Alizyme

  • Collaboration and licensing strategies
  • Colonic drug delivery platform (COLALTM)
  • Prednisolone - MSBS for IBD
  • Renzapride for IBS
  • New approach to mucositis
  • 12:00 OXIS: THE ROLE OF OXIDATIVE STRESS IN INFLAMMATORY BOWEL DISEASE

    Dr Timothy C Rodell

    Dr Timothy C Rodell, President, OXIS Therapeutics

  • Relationship between oxidative stress and inflammation
  • Development of BXT-51072, a small molecule mimic of glutathione peroxidase (GPx) , for
  • inflammatory diseases
  • BXT-51072 in ulcerative colitis
  • 12:40 Lunch

    13:40 INVOLVEMENT OF TRYPTASE IN INFLAMMATORY DISEASES

    Dr Matthias C Kurth

    Dr Matthias C Kurth, Director, Clinical Sciences, Axys Pharmaceuticals

  • Transforming gene discoveries into drugs
  • Developing treatment for inflammatory bowel disease
  • Developing APC 2059
  • APC 2059, a class of synthetic small molecule compounds designed to inhibit tryptase
  • Taking APC 2059 into clinical trials
  • Benefits for the patient
  • 14:20 DEVELOPING TREATMENT FOR CROHN’S DISEASE

    Dr Paul Schendel

    Dr Paul Schendel, Senior Director, Project Management, Genetics Institute

  • Discovery, development and commercialisation of human pharmaceuticals through recombinant DNA
  • Finding treatment for inflammatory conditions
  • Finding new clinical indications for existing products and product development candidates
  • Using rhIL-11 for the treatment of Crohn’s disease
  • Taking rhIL-11 into clinical trials for the treatment of Crohn’s disease
  • Pharmacoeconomic aspects of using recombinant IL-11 for the treatment of Crohn’s disease
  • 15:00 EVALUATING LONG-TERM THERAPY FOR CROHN’S DISEASE WITH BIOLOGICS

    Dr Thomas F Schaible

    Dr Thomas F Schaible, Senior Director, Immunology Medical Affairs, Centocor

  • REMICADE™: mechanism of action
  • Treating moderately to severely active Crohn’s disease and fistulizing Crohn’s disease
  • Maintenance therapy for Crohn’s disease
  • Initiating a new clinical research program designed to evaluate the benefits of REMICADE™
  • Sustaining long-term clinical benefits for patients suffering from Crohn’s disease
  • Anticipating the future of treating Crohn’s disease
  • 15:40 Afternoon Tea

    16:00 BUSINESS STRATEGIES

    Dr William A Garland

    Dr William A Garland, Executive Vice President, Pharmaceutical Development, Centaur

  • Targeting large pharmaceutical markets with unmet medical needs
  • Expanding drug discovery efforts to include applications like inflammatory bowel disease
  • Developing NRTTMs, a novel class of small molecule pharmaceutical compounds
  • Establishing research programmes evaluating NRTs to treat inflammatory bowel disease
  • Maximising value added and know how through internal manufacturing
  • Seeking strategic collaborations with large pharmaceutical companies
  • 16:30 ANTI-DIARRHEAL COMBINATION THERAPY

    Dr Stephen Mann

    Dr Stephen Mann, Vice President, Research and Development, Johnson and Johnson MSD

  • Efficacy of loperamide in treating acute diarrhea
  • Producing significantly faster, more complete relief of acute, non specific diarrhea
  • Imodium: mechanism of action
  • Value of using a dual-ingredient product
  • Safety and efficacy of loperamide
  • Patient confidence in anti-diarrheal drugs
  • 17:00 Chairman's closing remarks and close of conference

    +

    Workshops

    Discovery to Peak Sales: A Vision
    Workshop

    Discovery to Peak Sales: A Vision

    The Hatton, at etc. venues
    13th October 1999
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.